Introduction to Bayesian methods III: Use and interpretation of Bayesian tools in design and analysis

Clinical Trials

Volumn 2, Issue 4, 2005, Pages 295-300

  Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTARABINE; IDARUBICIN; PRAVASTATIN; TRASTUZUMAB; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; BAYES THEOREM; BREAST CANCER; CLINICAL STUDY; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; MEDICAL INSTRUMENTATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; SAMPLE SIZE; SIMULATION; STATISTICAL MODEL;

BAYES THEOREM; ENDPOINT DETERMINATION; HUMANS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS;

EID: 24944510799     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774505cn100oa     Document Type: Conference Paper

References (11)

1. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin-containing chemotherapy: results of a randomized trial in HER-2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
2. Giles FJ, Kantarjian HM, Cortes JE et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003; 21: 1722-27.
3. Berry DA, Müller P, Grieve AP et al. Adaptive Bayesian designs for dose-ranging drug trials. In Gatsonis C, Carlin B, Carriquiry A, eds. Case studies in Bayesian statistics V., New York: Springer-Verlag, 2001, 88-181.
4. Inoue LYT, Thall P, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002; 58: 264-72.
5. Retrieved 7 June 2005 from: http://www.fda.gov/ohrms/ dockets/ac/02/slides/3829s2_03_Bristol-Meyers-meta analysis.ppt
6. Berry SM, Berry DA, Natarajan K, Lin C-S, Hennekens CH, Belder R. Bayesian survival analysis with nonproportional hazards: Metaanalysis of pravastatin-aspirin. J Am Stat Assoc 2004, 99: 36-44.
7. Berry DA. Statistical innovations in cancer research. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III, eds. Cancer medicine, sixth edition. London: BC Decker, 2003, 465-78.
8. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science 2004; 19: 175-87.
9. Couzin J. The new math of clinical trials. Science 2004; 303: 784-86.
10. Berry DA. Adaptive clinical trials and Bayesian statistics (with discussion). Pharmaceutical Report 2002; 9: 1-11.
11. Berry SM, Berry DA. Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixed model. Biometrics 2004, 60: 418-26.